Literature DB >> 26629004

MiR181c inhibits ovarian cancer metastasis and progression by targeting PRKCD expression.

Lijuan Yao1, Li Wang1, Fengxia Li2, Xihai Gao2, Xuegong Wei1, Zhihui Liu1.   

Abstract

MicroRNAs (miRNAs) regulate many important cancer related gene expression in the posttranscriptional process. Dysregulated expression of miRNAs has been observed in numerous human cancers including ovarian cancer. In this study, we found that the expression of the miR-181c was significantly decreased in ovarian cancer tissue and in tissues with lymph node metastasis when compared with their control samples, respectively. Moreover, among pathological stages, the expression of miR-181c was significantly decreased in the tissues with IV stage compared with other stages. In vitro, miR-181c significantly inhibited the proliferation, metastasis of A2780 cell line, and induced G1 phase arrest. Through bioinformatics prediction, protein kinase C delta (PRKCD) was identified as a target gene of miR-181c. Western blot results showed that PRKCD was increased in ovarian cancer tissue, in tissues with lymph node metastasis and IV stage of ovarian cancer pathological samples. After knocking down PRKCD, the cell cycle of A2780 cells was also arrested in G1 phase. The proliferation and the metastasis of A2780 cells were reduced. The dual luciferase reporter experiments showed that miR-181c regulated the expression of PRKCD by combining with its 3'UTR. These results indicate that miR-181c inhibits ovarian cancer metastasis and progression by targeting PRKCD expression.

Entities:  

Keywords:  Ovarian cancer; invasion and metastasis; miR-181c

Year:  2015        PMID: 26629004      PMCID: PMC4658893     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  23 in total

1.  Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum.

Authors:  Jaime Prat
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2015-03-07       Impact factor: 2.435

2.  Are RNAi and miRNA therapeutics truly dead?

Authors:  João Conde; Natalie Artzi
Journal:  Trends Biotechnol       Date:  2015-01-13       Impact factor: 19.536

3.  MicroRNA-181 functions as a tumor suppressor in non-small cell lung cancer (NSCLC) by targeting Bcl-2.

Authors:  Ping Huang; Bo Ye; Yu Yang; Jianxin Shi; Heng Zhao
Journal:  Tumour Biol       Date:  2014-12-20

4.  Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer.

Authors:  Vianey Gonzalez-Villasana; Enrique Fuentes-Mattei; Cristina Ivan; Heather J Dalton; Cristian Rodriguez-Aguayo; Ricardo J Fernandez-de Thomas; Burcu Aslan; Paloma Del C Monroig; Guermarie Velazquez-Torres; Rebecca A Previs; Sunila Pradeep; Nermin Kahraman; Huamin Wang; Pinar Kanlikilicer; Bulent Ozpolat; George Calin; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Clin Cancer Res       Date:  2015-01-16       Impact factor: 12.531

5.  Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia.

Authors:  Eric I Zimmerman; Claudia M Dollins; Melissa Crawford; Steven Grant; Serge P Nana-Sinkam; Kristy L Richards; Scott M Hammond; Lee M Graves
Journal:  Mol Pharmacol       Date:  2010-08-06       Impact factor: 4.436

6.  miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells.

Authors:  Xiaoling She; Zhibin Yu; Yulong Cui; Qianqian Lei; Zeyou Wang; Gang Xu; Zhaohui Luo; Guiyuan Li; Minghua Wu
Journal:  Med Oncol       Date:  2014-02-27       Impact factor: 3.064

7.  Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.

Authors:  Åslaug Helland; Michael S Anglesio; Joshy George; Prue A Cowin; Cameron N Johnstone; Colin M House; Karen E Sheppard; Dariush Etemadmoghadam; Nataliya Melnyk; Anil K Rustgi; Wayne A Phillips; Hilde Johnsen; Ruth Holm; Gunnar B Kristensen; Michael J Birrer; Richard B Pearson; Anne-Lise Børresen-Dale; David G Huntsman; Anna deFazio; Chad J Creighton; Gordon K Smyth; David D L Bowtell
Journal:  PLoS One       Date:  2011-04-13       Impact factor: 3.240

8.  microRNAs: short non-coding bullets of gain of function mutant p53 proteins.

Authors:  Sara Donzelli; Sabrina Strano; Giovanni Blandino
Journal:  Oncoscience       Date:  2014-06-07

9.  miR-874 functions as a tumor suppressor by inhibiting angiogenesis through STAT3/VEGF-A pathway in gastric cancer.

Authors:  Xiaoyu Zhang; Jie Tang; Xiaofei Zhi; Kunling Xie; Weizhi Wang; Zheng Li; Yi Zhu; Li Yang; Hao Xu; Zekuan Xu
Journal:  Oncotarget       Date:  2015-01-30

10.  Let-7, mir-98 and mir-183 as biomarkers for cancer and schizophrenia [corrected].

Authors:  Emmanouil Rizos; Nikolaos Siafakas; Eleni Katsantoni; Eleni Skourti; Vassilios Salpeas; Ioannis Rizos; James N Tsoporis; Anastasia Kastania; Anastasia Filippopoulou; Nikolaos Xiros; Demetrios Margaritis; Thomas G Parker; Charalabos Papageorgiou; Vassilios Zoumpourlis
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

View more
  10 in total

1.  Hepatitis C Virus Mediated Inhibition of miR-181c Activates ATM Signaling and Promotes Hepatocyte Growth.

Authors:  Tapas Patra; Keith Meyer; Ratna B Ray; Ranjit Ray
Journal:  Hepatology       Date:  2019-11-03       Impact factor: 17.425

2.  Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.

Authors:  Elizabeth A Mazzio; Karam F A Soliman
Journal:  Cancer Genomics Proteomics       Date:  2018 Sep-Oct       Impact factor: 4.069

Review 3.  Potential microRNA-related Targets for Therapeutic Intervention with Ovarian Cancer Metastasis.

Authors:  Ulrich H Weidle; Fabian Birzele; Gwen Kollmorgen; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2018 Jan-Feb       Impact factor: 4.069

4.  Development and validation of a novel survival model for acute myeloid leukemia based on autophagy-related genes.

Authors:  Li Huang; Lier Lin; Xiangjun Fu; Can Meng
Journal:  PeerJ       Date:  2021-08-12       Impact factor: 2.984

5.  Bone marrow stromal cells-derived microRNA-181-containing extracellular vesicles inhibit ovarian cancer cell chemoresistance by downregulating MEST via the Wnt/β-catenin signaling pathway.

Authors:  Zhengyi Ruan; Lili Lu; Li Zhang; Min Dong
Journal:  Cancer Gene Ther       Date:  2020-07-07       Impact factor: 5.987

Review 6.  Ovarian Aging: Role of Pituitary-Ovarian Axis Hormones and ncRNAs in Regulating Ovarian Mitochondrial Activity.

Authors:  Marco Colella; Danila Cuomo; Teresa Peluso; Ilaria Falanga; Massimo Mallardo; Mario De Felice; Concetta Ambrosino
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-16       Impact factor: 5.555

Review 7.  Epi-miRNAs: Regulators of the Histone Modification Machinery in Human Cancer.

Authors:  Deniz Mortazavi; Behnoush Sohrabi; Meysam Mosallaei; Ziba Nariman-Saleh-Fam; Milad Bastami; Yaser Mansoori; Abdolreza Daraei; Sepideh Zununi Vahed; Shadan Navid; Zahra Saadatian; Tannaz Jamialahmadi; Yong Teng; Amirhossein Sahebkar
Journal:  J Oncol       Date:  2022-01-11       Impact factor: 4.375

8.  MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway.

Authors:  Li-Ying Zhang; Jia-Ying Yu; Yan-Long Leng; Ran-Ran Zhu; Hong-Xian Liu; Xin-Yu Wang; Ting-Ting Yang; Yi-Ning Guo; Jing-Ling Tang; Xin-Chen Zhang
Journal:  Cancer Gene Ther       Date:  2021-06-18       Impact factor: 5.854

9.  Integrative landscape of dysregulated signaling pathways of clinically distinct pancreatic cancer subtypes.

Authors:  Musalula Sinkala; Nicola Mulder; Darren Patrick Martin
Journal:  Oncotarget       Date:  2018-06-26

Review 10.  Small Non-Coding-RNA in Gynecological Malignancies.

Authors:  Shailendra Kumar Dhar Dwivedi; Geeta Rao; Anindya Dey; Priyabrata Mukherjee; Jonathan D Wren; Resham Bhattacharya
Journal:  Cancers (Basel)       Date:  2021-03-03       Impact factor: 6.575

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.